Molecular, biochemical and genetic characterization of ornithine decarboxylase, S-adenosylmethionine decarboxylase and spermidine synthase establishes that these polyamine-biosynthetic enzymes are essential for growth and survival of the agents that cause African sleeping sickness, Chagas' disease, leishmaniasis and malaria. These enzymes exhibit features that differ significantly between the parasites and the human host. Therefore it is conceivable that exploitation of such differences can lead to the design of new inhibitors that will selectively kill the parasites while exerting minimal, or at least tolerable, effects on the parasite-infected patient.
Introduction
Parasitic protozoa continue to beleaguer and kill millions of people in the subtropical and tropical regions of the world. However, some new inroads towards improved treatments of malaria, leishmaniasis, Chagas' disease and African sleeping sickness, diseases caused by protozoan parasites, have been made. One pathway that has been exploited successfully in the treatment of parasitic diseases is that of polyamine biosynthesis ( Figure 1 ). Treatment with D,L-α-difluoromethylornithine (DFMO), an inhibitor of the first enzyme in the polyamine biosynthetic pathway, was found to cure mice infected with Trypanosoma brucei brucei, a parasite that is closely related to the trypanosomes that cause sleeping sickness in humans [1] . DFMO treatment was subsequently found to eradicate Trypanosoma brucei gambiense infections in patients with West African sleeping sickness, even after central nervous system involvment [2] . Other protozoan parasites also depend on polyamines for growth and survival. Because the polyamine biosynthetic enzymes of the parasites seem to exhibit features that are significantly different from those of the human host and also because some enzymes that use polyamines as substrates are unique to the parasites, it is conceivable that exploitation of this pathway could lead to the design of new antiparasitic drugs that will selectively kill the parasites.
ornithine to putrescine ( Figure 1 ). S-Adenosylmethionine decarboxylase (AdoMetDC) generates decarboxylated S-adenosylmethionine (dcAdoMet), which serves as the aminopropyl group donor for spermidine and spermine synthesis. The latter reactions are catalysed by spermidine synthase and spermine synthase, respectively ( Figure 1A ). Prokaryotes and lower eukaryotes, including the protozoan parasites, either lack or appear to lack spermine synthase ( Figures 1B-1D ). Nevertheless, some parasites contain spermine, most likely as a result of uptake from their host.
So-called 'suicide inhibitors' have been developed for all four biosynthetic enzymes (see [3] and references therein). Their mechanism of action is based on activation by the target enzyme, which ensures high specificity for each of these irreversible inhibitors. Other types of drugs, which interfere with the functions of polyamines, are the structural analogues.
African sleeping sickness (African trypanosomiasis)
The causative agent of African sleeping sickness is T. brucei, a protozoan transmitted to humans in the equatorial region of Africa by the bite of flies of the genus Glossina. The infective trypomastigotes, formed from epimastigotes in the salivary glands of the tsetse fly, find their way from the wound created by the bite into blood, lymph and eventually cerebrospinal fluid.
DFMO is effective against both early-and late-stage West African sleeping sickness caused by T. b. gambiense [2] . Unfortunately, the East African form of the disease, caused by Trypanosoma brucei rhodesiense, is largely unaffected by the drug. The reason for this difference has not been clarified but may be a function of the more rapid progression of the latter disease. While the high efficacy of DFMO against T. b. gambiense infections in humans may have multiple AdoMetDC, S-adenosylmethionine decarboxylase; dcAdoMet, decarboxylated AdoMet; GSH, glutathione; GSS, glutathionylspermidine synthase; MTA, 5 -methylthioadenosine; Orn, ornithine; ODC, ornithine decarboxylase; SAT, spermidine/ spermine-N 1 -acetyltransferase; PAO, polyamine oxidase; ROS, reactive oxygen species; SpdS, spermidine synthase; SpmS, spermine synthase; T, polyamine-transport system; TryR, trypanothione reductase; TryS, trypanothione synthase.
causes, the primary basis is probably the dramatic discrepancy in stability between the host and parasite ODC enzymes [4] . The parasitic ODC is quite stable (t 1/2 > 6 h) whereas the human enzyme turns over rapidly (t 1/2 < 1 h). This implies that newly synthesized, active ODC rapidly replaces DFMOinactivated ODC in the human host but not in the parasite where the turnover rate of the enzyme is slow. The C-terminal region of human ODC appears to be essential for the rapid degradation of the protein. Since there is no corresponding domain in T. brucei ODC, the stability of this protein has been attributed to the lack of this C-terminal domain, i.e. removal of a degradation signal [4] . However, the finding that ODC of another trypanosomatid, Crithidia fasciculata, turns over rapidly despite lacking the corresponding domain, indicates that other motifs on the protein may mediate the targeting of ODC for rapid degradation [5] .
The reduced production of putrescine and spermidine in T. brucei apparently cannot be compensated for by uptake of polyamines from the blood of the host, either because of the inefficient polyamine-transport system of this parasite or the low levels of polyamines available to the parasite in the blood ( Figure 1B) . However, other trypanosomatids, such as Trypanosoma cruzi, appear to be absolutely dependent upon polyamine uptake for their growth and survival and have developed a very efficient putrescine-uptake system ( Figure 1C ) [6] . T. cruzi also invade host cells where the polyamine concentration is significantly higher than in the serum.
Because of the DFMO-mediated depletion of intracellular spermidine, the parasites cannot synthesize trypanothione, a conjugate of spermidine and glutathione that is unique to trypanosomes and Leishmania ( Figure 1B ) [7] . Trypanothione is a reducing agent with many protective and regulatory functions, and consequently its depletion in DFMO-treated parasites is detrimental to the parasite.
T. b. brucei strains lacking both wild-type ODC alleles have been created by double-targeted gene replacement [8] .
These ∆odc-null mutants require exogenous putrescine for proliferation. When injected into mice, a bloodstream form of the ∆odc mutant was unable to multiply and was quickly cleared from the blood, presumably because of the low levels of polyamines available to the parasites in the blood [9] .
Irreversible inhibition of AdoMetDC, using 5 -{[(Z)-4-amino-2-butenyl]methylamino}-5 -deoxyadenosine (MDL 73811; AbeAdo), a structural analogue of dcAdoMet, was found to be very effective against T. b. brucei infections in mice and rats [10] . Since the trypanosomes disappeared from the bloodstream before polyamine depletion, the anti-trypanosomal effect was attributed to a dramatic increase in the level of S-adenosylmethionine (AdoMet), the universal methyl donor, that correlated with the decrease in parasitaemia. This accumulation of AdoMet may cause aberrant methylation, which in turn may interfere with growth and survival of the parasite. AbeAdo was much more potent than DFMO, and combinations of the two drugs were synergistic, even curing mice infected with clinical isolates of T. b. rhodesiense [11] . These data indicate that by inhibiting both ODC and AdoMetDC, it may be possible to achieve effective therapy against East African sleeping sickness, even drug-refractory and late-stage forms.
Chagas' disease (American trypanosomiasis)
Chagas' disease is a severely debilitating infection that is distributed widely in rural zones of Latin America. The causative agent is T. cruzi, transmitted by blood-sucking insects of the subfamily Triatominae. The infective trypomastigotes, present in the faeces of the bug, enter the bite wound and migrate to various tissues, where they become intracellular replicating amastigotes. Other routes of transmission include blood transfusion or organ transplantation from an infected donor, as well as congenital transmission from an infected mother.
T. cruzi lacks ODC and therefore cannot synthesize putrescine de novo ( Figure 1C ) [12, 13] . Although there is some evidence to suggest that T. cruzi can generate putrescine from arginine via agmatine [14] , it seems more likely that the parasite relies on putrescine uptake and AdoMetDC for spermidine synthesis [7, 12, 13] . In fact, putrescine uptake is 10-50-fold higher in T. cruzi than in Leishmania mexicana and C. fasciculata [6] . Lack of ODC and the inability to synthesize putrescine is consistent with the following findings : (i) that T. cruzi is dependent on uptake of diamines [15] , (ii) that DFMO is completely inactive against all stages of the parasite, (iii) that expression of a foreign ODC gene in T. cruzi overcomes the requirement of exogenous polyamines for growth [15] and (iv) that DFMO treatment causes growth arrest of T. cruzi that express a foreign ODC [16] .
Methylglyoxal-bis(guanylhydrazone) (MGBG), a potent inhibitor of human AdoMetDC, is a poor inhibitor of the T. cruzi enzyme [12] . Likewise, some aromatic derivatives of MGBG, which show trypanocidal effects against T. b. brucei and T. b. rhodesiense, are inactive against T. cruzi amastigotes in murine macrophages in vitro [17] . Nevertheless, the differential sensitivity to MGBG suggests that the human and T. cruzi AdoMetDCs are sufficiently dissimilar to warrant the design of structure-based compounds that might selectively interfere with growth and survival of the parasite without seriously affecting the human host. Thus far, only the crystal structure of human AdoMetDC has been determined [18] .
Considering the efficiency of the polyamine transporter(s) in T. cruzi, it seems unlikely that the intracellular amastigote form of the parasite can be killed by using inhibitors of AdoMetDC or spermidine synthase. The host cells constitute a rich source of polyamines, and the polyamine transporter(s) of the parasite probably has to be blocked to confer a polyamine-deficient state. Of further interest is the fact that in T. cruzi a single enzyme catalyses the formation of trypanothione from spermidine and glutathione ( Figure 1C ) [19] .
Visceral leishmaniasis (Kala-azar)
Leishmania donovani and Leishmania infantum are causative agents of visceral leishmaniasis, a devastating and often fatal disease in humans. The parasites exhibit a digenetic life cycle; the motile, extracellular promastigote resides in a sandfly vector of the genus Phlebotomus, and the non-motile, intracellular amastigote propagates within the phagolysosomes of macrophages in the human host.
DFMO, as well as several other fluorinated ornithine analogues, are cytotoxic not only to T. brucei spp. but also to L. donovani [20] and L. infantum [21] promastigotes. As in the case of trypanosomal ODC [4] , leishmanial ODC exhibits a long half-life (>20 h) that is attributable to the lack of a C-terminal extension [22] .
To investigate the importance of ODC, AdoMetDC and spermidine synthase ( Figure 1B) in L. donovani, the genes encoding these enzymes were cloned and sequenced [22] [23] [24] [25] . The corresponding null mutants (∆odc, ∆adometdc and ∆spds) were created in promastigotes by double-targeted gene replacement [23] [24] [25] . The ∆odc-knockout strain lacking both ODC alleles was incapable of growth in polyaminedeficient medium [23] . This auxotrophy could be overcome by addition of putrescine or spermidine, but not spermine. Putrescine restored the intracellular pools of both putrescine and spermidine, but spermidine was not converted back into putrescine. These findings indicate that spermidine alone is sufficient to meet the polyamine requirement for growth and that L. donovani lacks the polyamine back-conversion pathway (cf. Figures 1A and 1B) [23] .
∆adometdc and ∆spds mutants were also incapable of growth in medium without polyamines [24, 25] . Auxotrophy could be overcome by spermidine but not by putrescine or spermine. AdoMetDC overexpression, resulting from transfection and amplification of an episomal AdoMetDC construct, abrogated polyamine auxotrophy in the AdoMetDC-deficient mutants and alleviated the toxic effects of AbeAdo in wild-type parasites [24] . The stability of L. donovani AdoMetDC (t 1/2 > 24 h) and the lability of the human enzyme suggests that irreversible inhibitors of AdoMetDC may also be able to eradicate leishmanial infections, depending upon the precise polyamine content of the intracellular milieu in which the parasites reside. Since spermidine synthase is a stable enzyme in both L. donovani and human cells [25] , inhibitors of both enzymes are likely to affect parasite and host cells similarly, unless structural differences can be exploited to selectively target the parasite enzyme.
Malaria
Malaria, which is caused by protozoan parasites of the genus Plasmodium, affects up to 500 million individuals and kills over 1 million people every year, mainly in sub-Saharan Africa. These parasites require two hosts : the Anopheles mosquito for the sexual reproductive stages, and humans for the asexual reproductive stages. The infectious sporozoites are injected by the mosquito into blood vessels in the skin. They invade hepatocytes and begin the exoerythrocytic cycle, which generates thousands of merozoites (schizogony). After rupture of the hepatocyte, the merozoites enter the bloodstream and begin the erythrocytic cycle by invading red blood cells, forming trophozoites. Replication in the erythrocyte (schizogony) culminates in rupture and release of a small number of merozoites, which initiate another cycle of replication by infecting other erythrocytes.
The life cycle of Plasmodium can be interrupted at several stages by treatment with ODC inhibitors. When administered to the mosquito vector, DFMO inhibits the sporogonous cycle of Plasmodium berghei, and mice bitten by the mosquitoes do not contract malaria [26] . DFMO also blocks exoerythrocytic schizogony and limits erythrocytic schizogony of P. berghei in mice [27] . Several ODC inhibitors inhibit erythrocytic schizogony of Plasmodium falciparum in vitro. In human P. falciparum-infected erythrocytes, DFMO inhibits growth and maturation of the intracellular parasite at the trophozoite stage [28] . Irreversible inhibition of AdoMetDC with AbeAdo causes similar effects against chloroquine-resistant strains of P. falciparum [29] .
When the polyamine biosynthetic enzymes from P. falciparum, the deadliest malaria parasite, were studied at the molecular level, it was demonstrated that the ODC and AdoMetDC enzymes were components of a bifunctional protein ( Figure 1D ) [30, 31] . The N-terminal region of the newly synthesized protein contains an AdoMetDC proenzyme, which cleaves itself to produce an active enzyme with a catalytically essential pyruvoyl residue at the new N-terminus. The AdoMet domain is connected to the C-terminal ODC domain through a hinge domain. The mature enzyme is a heterotetrameric complex, containing two sets of the cleavage products. The significance of the bifunctional nature of this protein remains obscure, but the unique organization of AdoMetDC and ODC may offer the possibility of therapeutic intervention, particularly because of regulatory differences between the enzymes of the parasite and the human host cells [32] .
Conclusions
Analyses of knockout strains of T. b. brucei and L. donovani lacking ODC, AdoMetDC or spermidine synthase clearly show that these parasites cannot survive unless they can access sufficient amounts of exogenous putrescine or spermidine. Wild-type T. cruzi, which are naturally ODC-deficient, also depend on exogenous putrescine or spermidine for their survival. Trypanocidal activities of inhibitors of the polyamine biosynthetic enzymes further underscore the relevance of this pathway as a therapeutic target. As the threedimensional structures for these enzymes become known it may be possible to design structure-based inhibitors that will selectively kill the parasites while exerting minimal or at least tolerable effects on the parasite-infected patient. However, intracellular parasites may not be amenable to drug-mediated polyamine depletion, unless polyamine-uptake mechanisms can be blocked.
